Diagnosis, prognosis and therapeutic control of malignant diseases using PLA2R1 methylation analysis
The invention relates to the field of medicine, specifically to the diagnostics, prognosis and therapy control of tumour diseases. The invention is based on the hitherto unknown epigenetic silencing, discovered by chance by the inventors, of the phospholipase-A2-receptor-1-coding gene in leukaemia cells and in patients suffering from leukaemias and solid tumours. Based on this finding, the invention provides methods and a kit with which the degree of methylation of the phospholipase-A2-receptor-1 gene in an isolated sample of the patient is determined.
Property right: DE102010031354B3; WO002012007462A1
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…